Covered recipient · General Payments record
ALYSSA PERCHINSKE
Physician Assistants & Advanced Practice Nursing Providers Nurse Practitioner
General Payments · PY2023–2024
$391.18
- Reported across 21 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $305.32 | 16 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Acerta Pharma LLC | $74.06 | 4 |
| ABBVIE INC. | $66.72 | 3 |
| Amgen Inc. | $52.61 | 2 |
| PFIZER INC. | $34.83 | 2 |
| Lilly USA, LLC | $28.55 | 2 |
| Xeris Pharmaceuticals, Inc. | $21.25 | 1 |
| GlaxoSmithKline, LLC. | $13.80 | 1 |
| Novo Nordisk AS | $13.50 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $21.95 | 01/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107832810 | CMS |
| ABBVIE INC. | $24.07 | 04/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107832812 | CMS |
| ABBVIE INC. | $20.70 | 10/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107832814 | CMS |
| Amgen Inc. | $21.00 | 04/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116010487 | CMS |
| Amgen Inc. | $31.61 | 11/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116010495 | CMS |
| AstraZeneca Pharmaceuticals LP | $20.88 | 02/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104759342 | CMS |
| AstraZeneca Pharmaceuticals LP | $17.93 | 05/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104305838 | CMS |
| AstraZeneca Pharmaceuticals LP | $18.30 | 07/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104198565 | CMS |
| AstraZeneca Pharmaceuticals LP | $16.95 | 07/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104374711 | CMS |
| GlaxoSmithKline, LLC. | $13.80 | 05/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116283966 | CMS |
| Lilly USA, LLC | $14.00 | 09/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135488894 | CMS |
| Lilly USA, LLC | $14.55 | 12/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135445467 | CMS |
| Novo Nordisk Inc | $13.50 | 07/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100459016 | CMS |
| PFIZER INC. | $19.35 | 03/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1132031681 | CMS |
| PFIZER INC. | $15.48 | 05/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131603093 | CMS |
| Xeris Pharmaceuticals, Inc. | $21.25 | 07/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1144619293 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2023, 2024
- Source files
- Dataset page · Bulk file · PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.